Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024

Rhea-AI Summary

Alpha Cognition (NASDAQ: ACOG) demonstrated significant growth in 2024, successfully raising $52.8 million and completing its NASDAQ uplisting. The company achieved several key milestones, including completing commercial manufacturing for its lead product ZUNVEYL (benzgalantamine), securing a U.S. patent extending protection through 2044, and finalizing phase one of a Department of Defense-funded study for head trauma treatment.

Notable achievements include a successful launch in the U.S. Long-Term Care (LTC) market, estimated at $2 billion, and securing a $44 million licensing agreement for Asia. The company reports positive initial physician feedback and is actively building international partnerships to diversify revenue streams.

Positive

• Raised $52.8M and completed NASDAQ uplisting
• Secured $44M licensing deal for Asian market
• Completed commercial manufacturing for ZUNVEYL
• Extended patent protection through 2044
• Successfully launched in $2B LTC market
• Positive physician feedback in initial launch

Negative

• None.

News Market Reaction

+4.74%

1 alert

+4.74% News Effect

On the day this news was published, ACOG gained 4.74%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Dallas, Texas--(Newsfile Corp. - April 1, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition had a strong 2024 after raising $52.8M and uplisting to NASDAQ, significantly enhancing its capital base and market visibility. It completed commercial manufacturing for its lead product ZUNVEYL (benzgalantamine), secured a new U.S. patent extending exclusivity through 2044, and concluded phase one of a Department of Defense-funded study demonstrating the potential to treat head trauma from blasts.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Successfully launched in U.S. LTC market; raised $52.8M, uplisted to Nasdaq (ACOG), and secured patent protection through 2044.
• Signed $44M licensing deal for Asia; building international partnerships to diversify revenue and reduce risk.
• Strong start in $2B LTC market with experienced sales team; positive initial physician feedback driving awareness and adoption.

Click image above to view full announcement.

---

About Stonegate

Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.

Contacts:

Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247008

FAQ

What major funding did Alpha Cognition (ACOG) secure in 2024?

Alpha Cognition raised $52.8 million and successfully uplisted to NASDAQ in 2024.

How long is ACOG's patent protection for ZUNVEYL extended?

Alpha Cognition secured a new U.S. patent extending protection through 2044.

What is the value of ACOG's Asian licensing deal?

Alpha Cognition signed a $44 million licensing deal for the Asian market.

What is the estimated market size for ACOG's LTC segment?

The Long-Term Care (LTC) market where ACOG launched is estimated at $2 billion.

What progress has ACOG made with the Department of Defense?

ACOG completed phase one of a DoD-funded study showing potential for treating blast-related head trauma.